AUS
NZ
UK
CA
USA
IND
The share price of AstraZeneca (LSE:AZN) experienced a significant decline on Tuesday following disappointing updates from the company's latest lung cancer trials. The stock fell 4.2% to 12,182p by 11:49 BST, having previously dropped by as much as 5.6% earlier in the day.
The negative reaction stemmed from a presentation at the IASLC 2024 World Conference on Lung Cancer held in San Diego. During the conference, AstraZeneca and Daiichi Sankyo revealed that the TROPION-Lung01 trial results did not achieve statistical significance for overall survival rates. This trial assessed the effectiveness of datopotamab deruxtecan, also known as Dato-DXd, compared to the current standard of care, docetaxel, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who had undergone at least one prior line of therapy.
Despite the trial’s failure to meet statistical significance benchmarks, AstraZeneca highlighted that the detailed phase III trial results still indicated a "clinically meaningful trend" favoring Dato-DXd over docetaxel. The company emphasized that this data, along with findings from the TROP2-QCS biomarker studies and the NeoCOAST-2 trial in early-stage disease, reinforces their belief in the potential of datopotamab deruxtecan to significantly impact the treatment landscape for NSCLC across various stages and settings.
Susan Galbraith, AstraZeneca’s executive vice president of Oncology R&D, expressed confidence in the drug's potential role, stating that these results underline its importance in advancing treatment options for non-small cell lung cancer. The company remains optimistic about the future impact of Dato-DXd, despite the setback in the latest trial results.
The market’s reaction reflects concerns about the trial’s outcome and its implications for AstraZeneca’s oncology pipeline. The company’s share price decline highlights the sensitivity of biotechnology stocks to clinical trial results and the high stakes involved in developing effective cancer treatments.
